Pacific Biosciences of California, Inc. (PACB)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$2.55+4.51%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · PACB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 92.8% |
| Our one-year growth estimate | diamond | 18.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 74.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 28 industry peers · Company calendar date is not available
PACB — CEO transition
Dated 2026-11-04
CFO — Jim Gibson: The CFO transitioned to an advisory role with an interim successor appointed by the CEO, indicating an orderly succession rather than a sudden loss of executive leadership.
Why it matters: PacBio cut its 2026 revenue range to $155 million-$165 million in Q2. Q3 revenue will show whether sales are near the new path.
Watch forQ3 revenue is at least $39 million, putting the company on pace for the $155 million low end based on Q1 and Q2 results.
Also watch forQ3 revenue is below $39 million, making the $155 million full-year low end harder to reach.
Why it matters: Management set a target to cut yearly operating costs by $30 million-$40 million by end-2027. The next update can show the pace and cost of the plan.
Supportive ifManagement reports a dated plan with yearly cost savings on pace to reach $30 million-$40 million by end-2027.
Worry ifManagement cuts the savings target, delays the end-2027 goal, or says yearly savings are below plan.
Why it matters: Mark Van Oene took over as CEO in August. His first earnings update can clarify plans for sales, costs, and the 2026 revenue target.
Watch forAt the Nov. 4 earnings update, the CEO keeps the $155 million-$165 million revenue range and gives clear milestones for cost cuts and SPRQ-Nx.
Also watch forAt the Nov. 4 update, the CEO cuts the revenue range or delays the stated cost-cut or SPRQ-Nx plans.
Why it matters: Q2 non-GAAP gross margin fell to 36% from 38% a year earlier. PacBio cited compute and memory costs, Vega costs, and lower Revio prices.
Watch forQ3 non-GAAP gross margin is above 36%, showing a gain from Q2.
Also watch forQ3 non-GAAP gross margin is 36% or lower, showing no recovery from Q2.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$351 on $10,000 · ±3.5% | How much price usually moves either way. |
| Bad day | $942 loss on $10,000 · 9.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,843 loss on $10,000 · 58.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Revio placements rose to 20 in Q2, but use per system fell to about $202,000 a year. More systems and steady use can support consumable sales.
Watch forQ3 Revio placements exceed 20 and annual use per system is at least $202,000.
Also watch forQ3 Revio placements are below 20, or annual use per system falls below $202,000.